Leaflet PRAMIPEXOL SANDOZ 2.1mg prolonged-release tablets


Indicated for: Parkinson's disease

Route of administration: oral

Substance: pramipexole (antiparkinsonian agent)

ATC: N04BC05 (Nervous system | Dopaminergic agents | Dopamine agonists)

Pramipexole is a dopamine receptor agonist used for the treatment of Parkinson's disease and restless legs syndrome. It works by stimulating dopamine receptors in the brain, alleviating motor and non-motor symptoms.

The medication is taken orally, as directed by a doctor, usually once to three times daily. It is important for patients to follow the treatment regimen and inform the doctor about any other medications being used.

Patients should be aware of potential side effects, such as drowsiness, dizziness, or nausea. It is important to inform the doctor of any unusual symptoms.

Common side effects include drowsiness, dizziness, and nausea. In rare cases, severe reactions such as hallucinations or compulsive behaviors may occur. Patients should be informed of these risks before use.

General data about PRAMIPEXOL SANDOZ 2.1mg

  • Substance: pramipexole
  • Date of last drug list: 01-08-2019
  • Commercial code: W66160001
  • Concentration: 2.1mg
  • Pharmaceutical form: prolonged-release tablets
  • Quantity: 10
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: FERRER INTERNACIONAL, S.A. - SPANIA
  • Holder: S.C. SANDOZ S.R.L. - ROMANIA
  • Number: 6750/2014/01
  • Shelf life: 30 months

Pharmaceutical forms available for pramipexole

Concentrations available for pramipexole

  • 0.088mg
  • 0.18mg
  • 0.26mg
  • 0.35
  • 0.35mg
  • 0.52mg
  • 0.54mg
  • 0.70mg
  • 0.7mg
  • 1.05mg
  • 1.1mg
  • 1.57mg
  • 2.10mg
  • 2.1mg
  • 2.62mg
  • 3.15mg